首页> 外文期刊>Molecular pharmaceutics >In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents
【24h】

In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents

机译:氟康唑和双嘧达莫在胃肠道模拟器(GIS)中的体外溶出,预测减酸剂引起的体内溶出和药物相互作用

获取原文
获取原文并翻译 | 示例
       

摘要

Weakly basic drugs typically exhibit pH-dependent solubility in the physiological pH range, displaying supersaturation or precipitation along the gastrointestinal tract, Additionally, their oral bioavailabilities may be affected by coadministration of acid-reducing :agents that elevate gastric pH. The purpose of this study was to assess the feasibility of a multicompartmental in vitro dissolution apparatus, Gastrointestinal Simulator (GIS), in predicting in vivo dissolution of certain oral medications. In vitro dissolution studies of fluconazole, a BCS class I, and dipyridamole, a BCS class II weak bases (class IIb), were performed in the GIS as well as United States Pharmacopeia (USP) apparatus II and compared With the results of clinical drug drug interaction (DDI) studies. In both US? apparatus II and GIS, fluconazole completely dissolved within 60 min regardless of pH, reflecting no DDI between fluconazole and acid-reducing agents in a clinical study. On the other hand, seven-fold and 15-fold higher concentrations of dipyridamole than saturation solubility were observed in the intestinal Compartments in GIS with gastric pH 2.0. Precipitation of dipyridamole was also observed in the GIS, and the percentage of dipyridamole in solution was 45.2 +/- 7.0%. In GIS with gastric pH 6.0, mimicking the coadministration of acid-reducing agents, the concentration of dipyridamole was equal to its saturation solubility, and the percentage of drug in solution was 9.3 +/- 2.7%. These results are consistent with the clinical DDI study of dipyridamole with famotidine, which significantly reduced the C-max and area under the curve. An In situ mouse infusion study combined with GIS revealed that high concentration of dipyridamole in the GIS enhanced oral drug absorption, which confirmed the supersaturation of dipyridamole. In conclusion, GIS was shown to be a useful apparatus to predict in vivo dissolution for BCS class IIb drugs.
机译:弱碱性药物通常在生理pH范围内表现出pH依赖性溶解度,沿胃肠道表现出过饱和或沉淀。此外,它们的口服生物利用度可能会与降低胃酸的高酸药物共同给药而受到影响。这项研究的目的是评估一种多室体外溶出度计胃肠道模拟器(GIS)在预测某些口服药物在体内溶出度方面的可行性。在GIS和美国药典(USP)装置II中进行了氟康唑(BCS I类)和双嘧达莫(BCS II类弱碱)(IIb类)的体外溶出研究,并将其与临床药物的结果进行了比较药物相互作用(DDI)研究。在两个美国?根据仪器II和GIS,氟康唑在60分钟内完全溶解,而不管pH值如何,反映出在临床研究中氟康唑和减酸剂之间没有DDI。另一方面,在胃pH 2.0的GIS肠腔中,双嘧达莫的浓度比饱和溶解度高7倍和15倍。在GIS中也观察到双嘧达莫的沉淀,溶液中双嘧达莫的百分比为45.2 +/- 7.0%。在胃pH为6.0的GIS中,模仿降酸剂的共同给药,双嘧达莫的浓度等于其饱和溶解度,溶液中药物的百分比为9.3 +/- 2.7%。这些结果与双嘧达莫与法莫替丁的临床DDI研究一致,后者显着降低了C-max和曲线下面积。一项结合GIS的原位小鼠输注研究表明,GIS中的双嘧达莫的高浓度可增强口服药物的吸收,这证实了双嘧达莫的过饱和。总之,已证明GIS是预测BCS IIb类药物在体内溶解的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号